Blood components: red cells, platelets, plasma and cryoprecipitate, and when each is used
- Treatment and support
A donation is split into parts, and each part fixes one problem. Giving the right part, only when needed, is safer than giving blood 'to be sure'.
What it is
Donated whole blood is separated into components: red cells (to carry oxygen), platelets (to form the first plug), plasma (all the clotting factors) and cryoprecipitate (a concentrate of fibrinogen, factor VIII, von Willebrand factor and factor XIII made from plasma). Each is stored differently, carries different risks and answers a different clinical question. Special processing (leukoreduction, irradiation, washing) adapts a component to patients with particular risks.
What to know
- Red cells: given for symptomatic anaemia or active bleeding; most stable inpatients do well with a restrictive threshold of about 70 grams per litre, a little higher in heart disease or cardiac surgery.
- Platelets: given to prevent bleeding when the count is very low from marrow failure (around 10 × 10⁹/L in stable patients), or higher before procedures and in active bleeding (around 50, and about 100 for brain or eye surgery).
- Platelets are stored at room temperature, so they carry the highest risk of bacterial contamination of all components.
- Plasma replaces all clotting factors; it is for bleeding with abnormal clotting tests or massive transfusion, not for correcting a number in a patient who is not bleeding.
- Cryoprecipitate (or fibrinogen concentrate) is for bleeding with a low fibrinogen, as in massive haemorrhage, obstetric haemorrhage and DIC.
- Leukoreduction removes most donor white cells: fewer febrile reactions, less HLA alloimmunisation and less cytomegalovirus transmission.
- Irradiation stops donor lymphocytes from dividing and prevents transfusion-associated graft-versus-host disease; leukoreduction alone does not.
How it is done (and why)
- Name the problem: low oxygen delivery, low platelets, low clotting factors or low fibrinogen.
- Check whether it can be fixed without blood: iron, B12 or folate, stopping a drug, vitamin K, a concentrate.
- Decide by the patient, not the number alone: symptoms, bleeding, heart disease and the cause of the anaemia.
- Choose the component and any special requirement (irradiated, CMV-safe, washed, antigen-negative).
- Give the smallest effective amount, then reassess the patient and repeat the count before giving more.
- Record the indication, consent and response, and report any reaction to haemovigilance.
Four components, four jobs
| Component | What it replaces | Main uses | Storage and main risk |
|---|---|---|---|
| Red cells | Oxygen-carrying capacity | Symptomatic anaemia, active bleeding, chronic transfusion programmes (thalassaemia, some sickle cell) | Refrigerated for weeks; ABO mismatch, overload, iron overload with chronic use |
| Platelets | The primary plug | Marrow failure with very low count, bleeding or procedures with low or non-working platelets | Room temperature for days; bacterial contamination, poor rise if alloimmunised |
| Plasma | All clotting factors | Bleeding with prolonged PT or aPTT, massive transfusion, plasma exchange in TTP | Frozen; TRALI, allergic reactions, fluid overload |
| Cryoprecipitate | Fibrinogen (plus factor VIII, VWF, factor XIII) | Bleeding with low fibrinogen: massive or obstetric haemorrhage, DIC | Frozen; small volume, pooled from several donors |
Risks and precautions
- Every component can cause a reaction; volume overload is the commonest serious one in older patients and those with heart failure.
- Platelets help little in immune destruction (ITP) unless there is life-threatening bleeding, and are generally avoided in TTP and HIT outside life-threatening bleeding.
- Irradiated components are needed after stem cell transplant, in Hodgkin lymphoma, after purine analogue drugs, for intrauterine and neonatal exchange transfusions and for donations from relatives.
- Washed red cells are reserved for rare problems such as repeated severe allergic reactions despite premedication.
Monitoring and next step
- Before red cells: haemoglobin, a valid group and screen, and the cause of the anaemia.
- After platelets: a count about an hour later; a poor rise on repeated occasions suggests HLA alloimmunisation (look for HLA antibodies and give matched platelets).
- Before plasma or cryoprecipitate: PT, aPTT and fibrinogen; in massive bleeding, repeat them or use viscoelastic tests often.
- Any reaction during or after a component: stop and follow the reaction pathway (hmt_transfusion_reactions).
Common traps
- Transfusing to a number instead of the patient: a stable patient above the restrictive threshold usually gains nothing and takes on the risks.
- Giving plasma to 'correct' a mildly raised INR before a minor procedure in a patient who is not bleeding: it barely changes the INR and can cause TRALI or overload.
- Believing leukoreduction prevents graft-versus-host disease: only irradiation (or pathogen inactivation) does.
- Treating a low fibrinogen in massive bleeding with more plasma alone: plasma contains too little fibrinogen to raise it fast; cryoprecipitate or concentrate is needed.
- Giving platelets to every patient with a low count: in TTP and HIT they can feed the clotting.
Test yourself
Think of the answer, then tap the question to see it.
A bleeding patient has a low fibrinogen. Why is more plasma alone a poor way to correct it?
Plasma contains fibrinogen at normal plasma concentration only, so large volumes would be needed; cryoprecipitate or fibrinogen concentrate raises it faster with little volume.
Which component carries the highest risk of bacterial contamination, and why?
Platelets, because they are stored at room temperature, where bacteria introduced at collection can grow.
A patient after a stem cell transplant needs red cells. What special requirement matters most, and why?
Irradiation: it stops donor lymphocytes from dividing and prevents transfusion-associated graft-versus-host disease, which leukoreduction does not reliably prevent.
A stable ward patient has a haemoglobin just above the restrictive threshold and no symptoms. What next?
No transfusion: find and treat the cause of the anaemia, because transfusing above the threshold adds risk without clear benefit.
Elsewhere in DurgiPedia
- Blood groups, transfusion and transfusion reactions
- Transfusion thresholds in the ICU
- Blood transfusion: bedside checks, monitoring and reactions
- Complications of transfusion
- Graft-versus-host disease: the immunology
Connections
Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.
Sources: Blood Transfusion (StatPearls (NCBI Bookshelf), 2026); Blood Transfusion and Donation | MedlinePlus (MedlinePlus, US National Library of Medicine, 2026); Transfusion Reactions (StatPearls Publishing (NCBI Bookshelf), 2023); Informe Nacional de la Actividad Transfusional en Colombia 2023 (Instituto Nacional de Salud (Colombia), 2024).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
